Although these non-synaptic biomarkers demonstrated some effectiveness in the diagnosis of aMCI, SV2A-positive rates exceeded 90% in aMCI cases that were negative for NfL, GFAP, or p-tau217, which suggested that serum SV2A was more suitable as a screening indicator in the early stage of AD. This evidence concerns the gene NEFL and Alzheimer disease.